“A Study to Investigate How Well ABBV-323 Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy”
Study M15-722 is a Phase 2a study to investigate the efficacy and safety of ABBV-323 in participants with moderate to severe UC who failed prior therapy.
Drug - ABBV-323 Dose A
ABBV-323 Dose A is intravenously (IV) administered.
Drug - ABBV-323 Dose B
ABBV-323 Dose B is administered subcutaneously (SC).
A Multicenter, Single Arm, Open-label Study to Investigate the Efficacy and Safety of ABBV-323 in Subjects With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy